JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pardridge, W. M.
Right arrow Articles by Wu, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pardridge, W. M.
Right arrow Articles by Wu, D.

Vol. 286, Issue 1, 548-554, July 1998

Enhanced Endocytosis in Cultured Human Breast Carcinoma Cells and In Vivo Biodistribution in Rats of a Humanized Monoclonal Antibody after Cationization of the Protein1

William M. Pardridge, Jody Buciak, Jing Yang and Dafang Wu

Department of Medicine, UCLA School of Medicine, Los Angeles, California

For monoclonal antibody therapeutics to access target antigen in extravascular compartments, an antibody drug delivery technology is required that has the dual properties of 1) trans-endothelial migration of the antibody and 2) endocytosis of the antibody into the target cell. These two objectives may be achieved with antibody cationization, and the present studies examine the feasibility of cationizing the humanized 4D5 monoclonal antibody directed against the p185HER2 oncogenic protein. The cationized antibody binds to the p185HER2 extracellular domain with an ED50 of 35 µg/ml and inhibits SK-BR3 cell proliferation similar to the native antibody. Confocal microscopy showed that although there was binding of the native 4D5 antibody to the plasma membrane of SK-BR3 cells, this antibody was confined to the periplasma membrane space with minimal endocytosis into the cell. In contrast, robust internalization of the cationized 4D5 antibody by the SK-BR3 cells was demonstrated by confocal microscopy. The systemic volume of distribution of the cationized 4D5 antibody was 11-fold greater than that of the native antibody. In summary, these studies show that a humanized monoclonal antibody may be cationized with retention of antibody affinity for the target antigen and biological activity, yet with a marked alteration in the cellular distribution and pharmacokinetics in vivo.

0022-3565/98/2861-0548$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 JNMHome page
D. L. Costantini, C. Chan, Z. Cai, K. A. Vallis, and R. M. Reilly
111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
J. Nucl. Med., August 1, 2007; 48(8): 1357 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mandler, H. Kobayashi, E. R. Hinson, M. W. Brechbiel, and T. A. Waldmann
Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity
Cancer Res., February 15, 2004; 64(4): 1460 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Mandler, C. Wu, E. A. Sausville, A. J. Roettinger, D. J. Newman, D. K. Ho, C. R. King, D. Yang, M. E. Lippman, N. F. Landolfi, et al.
Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines
J Natl Cancer Inst, October 4, 2000; 92(19): 1573 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. X. Deng, E. Hanson, and I. Sanz
In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies
Int. Immunol., April 1, 2000; 12(4): 415 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Onda, R. J. Kreitman, G. Vasmatzis, B. Lee, and I. Pastan
Reduction of the Nonspecific Animal Toxicity of Anti-Tac(Fv)-PE38 by Mutations in the Framework Regions of the Fv Which Lower the Isoelectric Point
J. Immunol., December 1, 1999; 163(11): 6072 - 6077.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.